// App-Quantinova.ai

2691109 : Ceritinib is a more potent ALK inhibitor than crizotinib in uveal melanoma

Researchers

Presenter

  • Jade Marie Lasiste

Principal Investigators

  • Christina Mastromonaco

  • Prisca Raquel Bustamante

  • Jacqueline Coblentz

  • Laura Nunez

  • Patrick T Logan

  • Miguel N Burnier

Medical Centers

  • McGill University Health Centre, Montreal, QC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Anaplastic lymphoma Kinase

  • Vascular endothelial growth factor A

Drug/Treatment

  • Crizotinib

  • Alectinib

  • Ceritinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved